Interferon beta-1a - Faron Pharmaceuticals

Drug Profile

Interferon beta-1a - Faron Pharmaceuticals

Alternative Names: FP-1201; FP-1201-lyo; MR11A8; Recombinant human interferon beta-1a - Faron Pharmaceuticals; Traumakine

Latest Information Update: 29 Jun 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Faron Pharmaceuticals
  • Developer Faron Pharmaceuticals; Maruishi Pharmaceutical
  • Class Antineoplastics; Interferons
  • Mechanism of Action Immunostimulants; Interferon beta-1a-replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Adult respiratory distress syndrome; Acute lung injury
  • New Molecular Entity No

Highest Development Phases

  • Phase III Adult respiratory distress syndrome
  • Phase II Abdominal aortic aneurysm; Acute lung injury
  • Discontinued Brain injuries; Spinal cord injuries

Most Recent Events

  • 08 Jun 2018 Faron Pharmaceuticals terminates the phase III INTEREST trial since day 90 results indicated that IMP not reduced a mortality or ventilator free days for Adult respiratory distress syndrome in Finland, Germany, Spain, Czech Republic, Belgium, France, Italy and United Kingdom (IV) (NCT02622724)
  • 08 May 2018 Adverse events and efficacy data from the phase III INTEREST trial in Adult respiratory distress syndrome released by Faron Pharmaceuticals
  • 29 Jan 2018 Faron Pharmaceuticals announces intention to submit application for Orphan Drug Designation in Japan in 2018
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top